バイオ医薬品大手の独ビオンテックは5日、中国で行ってい る乳がん治療薬の第3相臨床試験(治験の最終段階)で重要な 目標である「無増悪生存期間(PFS)」を達成したことが、 中間分析で確認されたと…
バイオ医薬品大手の独ビオンテックは5日、中国で行ってい る乳がん治療薬の第3相臨床試験(治験の最終段階)で重要な 目標である「無増悪生存期間(PFS)」を達成したことが、 中間分析で確認されたと…
Cookie | 期間 | 説明 |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |